Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene

Journal of Virological Methods

Volumn 174, Issue 1-2, 2011, Pages 22-28

  Soprana, Elisa ^a   Panigada, Maddalena ^a,b   Knauf, Mathias ^c   Radaelli, Antonia ^b   Vigevani, Luisa ^a,b   Palini, Alessio ^a   Villa, Chiara ^a   Malnati, Mauro ^a   Cassina, Giulia ^a   Kurth, Reinhard ^c   Norley, Stephen ^c   Siccardi, Antonio G ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Prime boost pairs; Recombinant poxviruses

Indexed keywords

RED FLUORESCENT PROTEIN; VIRUS ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELL GROWTH; CHICK EMBRYO; CODON; CONTROLLED STUDY; CULTURE MEDIUM; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; FOWLPOX VIRUS; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; INFLUENZA VIRUS A H5N1; MAMMAL CELL; MODIFIED VACCINIA ANKARA VIRUS; NONHUMAN; PLASMID; PRIORITY JOURNAL; RELIABILITY; SEQUENCE HOMOLOGY; TRANSGENE; VACCINIA VIRUS; VIROGENESIS; VIRUS GENE; VIRUS PURIFICATION; VIRUS RECOMBINANT;

ANIMALS; CELL LINE; CHICKENS; DRUG CARRIERS; FOWLPOX VIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; TRANSDUCTION, GENETIC; TRANSGENES; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

AVES; FOWLPOX VIRUS; MAMMALIA;

EID: 79955772869     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.03.013     Document Type: Article

References (34)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002, 20:1949-1955.
2. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 2001, 75:5151-5158.
3. Carroll M.W., Overwijk W.W., Chamberlain R.S., Rosenberg S.A., Moss B., Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997, 15:387-394.
4. Carson C., Antoniou M., Ruiz-Arguello M.B., Alcami A., Christodoulou V., Messaritakis I., Blackwell J.M., Courtenay O. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 2009, 27:1080-1086.
5. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., Goebel F.D., Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003, 22:21-29.
6. Di Lullo G., Soprana E., Panigada M., Palini A., Agresti A., Comunian C., Milani A., Capua I., Erfle V., Siccardi A.G. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J. Virol. Methods 2010, 163:195-204.
7. Di Lullo G., Soprana E., Panigada M., Palini A., Erfle V., Staib C., Sutter G., Siccardi A. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. J. Virol. Methods 2009, 56:37-43.
8. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79(Pt 2):347-352.
9. Feng F., Teoh C.Q., Qiao Q., Boyle D., Jilbert A.R. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines. Vaccine 2010, 46:7436-7443. Epub 2010 Sep 15.
10. Grosenbach D., Barrientos J., Schlom J., Hodge J. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 2001, 61(June (11)). 61, 4497-4505.
11. Hanke T., Schneider J., Gilbert S.C., Hill A.V., McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998, 16:426-435.
12. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak M., Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 1996, 70:3741-3752.
13. Hodge J.W., Poole D.J., Aarts W.M., Gomez Yafal A., Gritz L., Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 2003, 63:7942-7949.
14. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., Bashir F., Bhatt K., Ogutu H., Wakasiaka S., Matu L., Waruingi W., Odada J., Oyaro M., Indangasi J., Ndinya-Achola J., Konde C., Mugisha E., Fast P., Schmidt C., Gilmour J., Tarragona T., Smith C., Barin B., Dally L., Johnson B., Muluubya A., Nielsen L., Hayes P., Boaz M., Hughes P., Hanke T., McMichael A., Bwayo J., Kaleebu P. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26:2788-2795.
15. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 1998, 72:10180-10188.
16. Kent S.J., Zhao A., Dale C.J., Land S., Boyle D.B., Ramshaw I.A. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 2000, 18:2250-2256.
17. Kotsopoulou E., Kim V.N., Kingsman A.J., Kingsman S.M., Mitrophanous K.A. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimised HIV-1 gag-pol gene. J. Virol. 2000, 74:4839-4852.
18. Malnati M.S., Scarlatti G., Gatto F., Salvatori F., Cassina G., Rutigliano T., Volpi R., Lusso P. A universal real-time PCR assay for the quantitation of group-M HIV-1 proviral load. Nat. Protoc. 2008, 3:1240-1248.
19. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., Hodge J.W., Doren S., Grosenbach D.W., Hwang J., Fox E., Odogwu L., Park S., Panicali D., Schlom J. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 2005, 23:720-731.
20. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 2003, 9:729-735.
21. Pozzi E., Basavecchia V., Zanotto C., Pacchioni S., De Giuli Morghen C., Radaelli A. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins. J. Virol. Methods 2009, 158:184-189.
22. Radaelli A., Bonduelle O., Beggio P., Mahe B., Pozzi E., Elli V., Paganini M., Zanotto C., De Giuli Morghen C., Combadiere B. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 2007, 25:2128-2138.
23. Restifo N.P., Minev B.R., Taggarse A.S., McFarland B.J., Wang M., Irvine K.R. Enhancing the recognition of tumour associated antigens. Folia Biol. (Praha) 1994, 40:74-88.
24. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., Hill A.V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4:397-402.
25. Southern J.A., Young D.F., Heaney F., Baumgärtner W.K., Randall R.E. Identification of an epitope on the P and V proteins of simian virus 5 that distinguishes between two isolates with different biological characteristics. J. Gen. Virol. 1991, 72:1551-1557.
26. Steensels M., Bublot M., Van Borm S., De Vriese J., Lambrecht B., Richard-Mazet A., Chanavat-Bizzini S., Duboeuf M., Le Gros F.X., van den Berg T. Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine 2009, 27:646-654.
27. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10847-10851.
28. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12:1032-1040.
29. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988, 6:497-503.
30. Tsang K.Y., Palena C., Yokokawa J., Arlen P.M., Gulley J.L., Mazzara G.P., Gritz L., Yafal A.G., Ogueta S., Greenhalgh P., Manson K., Panicali D., Schlom J. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin. Cancer Res. 2005, 11:1597-1607.
31. Wang M., Bronte V., Chen P.W., Gritz L., Panicali D., Rosenberg S.A., Restifo N.P. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 1995, 154:4685-4692.
32. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., Laidlaw S.M., Peto T., Skinner M.A., Gilbert S.C., Hill A.V. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006, 24:3026-3034.
33. Weidinger G., Ohlmann M., Schlereth B., Sutter G., Niewiesk S. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 2001, 19:2764-2768.
34. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14:1451-1458.